Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie

BioCryst Pharmaceuticals awarded $69M influenza treatment contract from U.S. HHS

…

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript

BCRX earnings call for the period ending June 30, 2024.…

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst to Report Second Quarter 2024 Financial Results on August 5

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Betting On BioCryst Pharmaceuticals: Orladeyos Success Fuels Future Prospects

…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

ORLADEYO® (berotralstat) Approved in Mexico

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript

BCRX earnings call for the period ending March 31, 2024.…

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

…

BioCryst Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the…

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript

BCRX earnings call for the period ending December 31, 2023.…

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

…

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses…

BioCryst Launches ORLADEYO® (berotralstat) in Italy

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Biocryst Pharmaceuticals, Biolase among healthcare movers

…

: Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Shares of Pharvaris N.V. PHVS jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its…

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BioCryst Launches ORLADEYO® (berotralstat) in Spain

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced updates…

BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2023.…

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript

…

BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stocks Bear Run

…

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment…

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that…

dpa-AFX ProFeed